Skip to main content

Select Drug Profiles

Perspectives
Navigating the “Hassle Map”
David B. Nash, MD, MBA
Read More
Practice Management
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges
Alan L. Shields, PhD, Yanni Hao, PhD, Meaghan Krohe, PhD, Andrew Yaworsky, Iyar Mazar, MA, Catherine Foley, MPH, MA, Faisal Mehmed, MD, Denise Globe, PhD
Stakeholder Perspective
Patient-Reported Outcomes in Oncology: Challenges and Opportunities for All Stakeholders
by Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Practice Management
Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States
S. Pinar Bilir, MS, Qiufei Ma, PhD, Zhongyun Zhao, PhD, Elizabeth Wehler, MPH, Julie Munakata, MS, Beth Barber, PhD
Stakeholder Perspective
Reducing Adverse Events and Healthcare Resource Waste by Careful Selection of the Best Drug Therapy
by James T. Kennedy, Jr, RPh, MBA
Read More
Original Research
Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials
Abdullah K. Alahmari, BPharm, PhD candidate, Ziyad S. Almalki, BPharm, PhD candidate, Ahmed K. Alahmari,, Medical Student, Jeff J. Guo, BPharm, PhD
Stakeholder Perspective
Better Patient Education Needed Regarding Thromboembolic Events Risk in Patients with Cancer
by Jeffrey A. Bourret, PharmD
Read More
FDA Approvals
Innovation Tops Current Trends in the 2016 Oncology Drug Pipeline
Dalia Buffery, MA, ABD
Read More
FDA Approvals, In the News
FDA Approves First Blood Test to Detect Gene Mutation Associated with Non–Small-Cell Lung Cancer
Read More
FDA Approvals, In the News
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
Read More
Perspectives
In Silico Pharmacology
David B. Nash, MD, MBA
Read More
Original Research
The Prevalence and Determinants of Controlled Substance Discrepancies in a Level I Trauma Hospital
Chukwuma Anyanwu, PharmD, MPH, MBA, Oliver Egwim, PharmD, MBA
Stakeholder Perspective
Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders
by Jack E. Fincham, PhD, RPh
Read More
Original Research
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation
Qing Lee, PhD, Michelle Mocarski, MPH, Shawn X. Sun, PhD
Stakeholder Perspective
Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden
by Gary Branning, MBA
Read More
Page 110 of 244
Results 1091 - 1100 of 2434